Reviewer’s report

Title: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

Version: 1 Date: 22 August 2007

Reviewer: Annamaria Ruzzo

Reviewer’s report:

General
The authors investigated the efficacy and toxicity of modified FOLFOX-6 chemotherapy in AGC patients. They also analyzed the predictive or prognostic value of polymorphisms of genes associated with 5-FU and oxaliplatin. The paper is interesting with positive results.

Major Compulsory Revisions
1- The authors do not mention how many cases are intestinal and diffuse gastric cancer. The two histological subtypes could influence the results.
2- It has been used in the analysis the Bonferroni’s correction? If not, Why?

Minor Essential Revisions
1- Nomenclature should be corrected through the paper: example XPD Arg156Arg instead of C156A

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:
I declare that I have no competing interests